Cerebrovascular Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CVA MCID: CRB039 MIFTS: 68	Cerebrovascular Disease (CVA) Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease ¹¹ ⁵³ ¹⁴ ⁷⁵

Cerebrovascular Disorders ⁴³ ⁷¹

Cerebrovascular Disorder ¹¹ ¹⁶

Cerebrovascular Accident ⁷¹

Stroke ¹¹

Cva ¹¹

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Neuronal diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the circulatory system

Cerebrovascular diseases

Cerebrovascular disorders in diseases classified elsewhere

Other cerebrovascular diseases

Cerebrovascular disease, unspecified

Other specified cerebrovascular diseases

ICD11: ³³

Diseases of the nervous system

Cerebrovascular diseases

Cerebrovascular disease with no acute cerebral symptom

Cerebrovascular disease with no acute cerebral symptom, unspecified

Other specified cerebrovascular disease with no acute cerebral symptom

Cerebrovascular diseases, unspecified

Certain specified cerebrovascular diseases

Other specified cerebrovascular disease

External Ids:

Disease Ontology ¹¹ DOID:6713

ICD9CM ³⁴ 437.9

MeSH ⁴³ D002561

NCIt ⁴⁹ C2938

SNOMED-CT ⁶⁸ 266312006

ICD10 ³¹ I60-I69 I67.8 I67.9 more

EFO ¹⁶ EFO_0003763

ICD11 ³³ 1935481507 1935481507/other 1935481507/unspecified more

UMLS ⁷¹ C0007820 C0038454

Sources

Summaries for Cerebrovascular Disease

Disease Ontology: ¹¹ An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary: Cerebrovascular Disease, also known as cerebrovascular disorders, is related to basal ganglia cerebrovascular disease and stroke, ischemic, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Signal Transduction and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). The drugs Acetylcarnitine and Nimodipine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone marrow and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: ⁷⁵ Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Sources

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2700)

#	Related Disease	Score	Top Affiliating Genes
1	basal ganglia cerebrovascular disease	33.0	PLAT APOE
2	stroke, ischemic	32.6	SERPINA3 SELP PON1 PLAT NOTCH3 MTHFR
3	cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1	32.6	SERPINA3 NOTCH3 COL4A1
4	vascular dementia	32.5	SERPINA3 PON1 NOTCH3 MTHFR CBS APP
5	peripheral artery disease	32.4	SELP APOE APOB ACE
6	binswanger's disease	32.4	NOTCH3 APP APOE ACHE
7	mitral valve stenosis	32.2	SERPINA3 SELP PLAT F2 ACE
8	transient cerebral ischemia	32.2	SERPINA3 PLAT NOTCH3 MTHFR F2 APOE
9	dementia	32.1	SERPINA3 PON1 NOTCH3 CBS APP APOE
10	disease of mental health	32.1	SERPINA3 APP APOE ACHE ACE
11	hemorrhage, intracerebral	32.0	PLAT COL4A1 APP APOE ACE
12	ischemia	32.0	SELP PON1 PLAT APP ACE
13	supranuclear palsy, progressive, 1	32.0	SERPINA3 CBS APP APOE ACHE
14	brain small vessel disease 1	31.9	NOTCH3 COL4A1
15	vascular disease	31.9	SELP PON1 PLAT NOTCH3 MTR MTHFR
16	carotid stenosis	31.9	SELP MTHFR APOE ACE
17	thoracic outlet syndrome	31.9	PLAT F2
18	alzheimer disease, familial, 1	31.7	SERPINA3 PON1 NOTCH3 MTR CBS APP
19	moyamoya disease 1	31.6	SERPINA3 PLAT NOTCH3 MTHFR F2 ACTA2
20	mild cognitive impairment	31.6	SERPINA3 APP APOE ACHE
21	peripheral vascular disease	31.5	SERPINA3 SELP PLAT MTHFR F2 CBS
22	thrombophilia due to thrombin defect	31.5	SELP PLAT MTHFR F2 CBS
23	coronary heart disease 1	31.5	PON1 CX3CR1 APOE APOB ACE
24	hypercholesterolemia, familial, 1	31.5	APOE APOB ACE
25	atrial heart septal defect	31.5	PLAT MTHFR F2 ACE
26	aortic valve disease 2	31.5	SERPINA3 APOB ACE
27	arteries, anomalies of	31.4	SERPINA3 APOE APOB AGTR1 ACE
28	atherosclerosis susceptibility	31.4	SELP PON1 PLAT MTHFR CX3CR1 APOE
29	heart disease	31.4	SERPINA3 SELP PON1 PLAT MTR MTHFR
30	lipoprotein quantitative trait locus	31.4	SERPINA3 SELP PON1 PLAT MTR MTHFR
31	cerebral amyloid angiopathy, cst3-related	31.4	SERPINA3 NOTCH3 APP APOE
32	arteriosclerosis	31.4	SELP PON1 CBS APOE APOB ACE
33	migraine with or without aura 1	31.4	SERPINA3 NOTCH3 MTHFR F2 COL4A1 APOE
34	arteriovenous malformation	31.4	SERPINA3 PLAT F2
35	lipid metabolism disorder	31.4	SERPINA3 PON1 CBS APOE APOB ACE
36	carotid artery disease	31.4	SELP PON1 PLAT APOE APOB ACE
37	aortic valve insufficiency	31.3	PON1 F2 ACTA2 ACE
38	hyperhomocysteinemia	31.3	SELP PON1 PLAT MTR MTHFR F2
39	intracranial embolism	31.3	SELP PLAT F2 APOE ACE
40	hemiplegia	31.3	PLAT COL4A1 ACTA2
41	nominal aphasia	31.3	CBS APOE ACHE
42	sleep apnea	31.3	APOE APOB ACE
43	hypertension, essential	31.2	SERPINA3 SELP PON1 PLAT MTHFR F2
44	aphasia	31.2	PLAT CBS APP APOE
45	deficiency anemia	31.2	SERPINA3 PON1 MTR F2 ACE
46	intracranial thrombosis	31.2	SELP PLAT MTHFR F2
47	attention deficit-hyperactivity disorder	31.2	SERPINA3 APP APOE ACHE ACE
48	hydrocephalus	31.2	SERPINA3 PLAT MTHFR APP APOE ACE
49	eclampsia	31.2	MTHFR F2 ACE
50	pre-eclampsia	31.2	SELP PON1 PLAT MTHFR HOTAIR F2

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 38)

Active Peptic Ulcer Disease	Acute Cystitis
Alzheimer Disease, Familial, 1	Anxiety
Aortic Valve Disease 1	Basilar Artery Insufficiency
Benign Essential Hypertension	Bronchitis
Cerebral Atherosclerosis	Cerebral Degeneration
Chronic Kidney Disease	Decubitus Ulcer
Deficiency Anemia	Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development	Esophagitis
Familial Atrial Fibrillation	Generalized Atherosclerosis
Heart Disease	Hypertension, Essential
Hypertensive Encephalopathy	Hypothyroidism
Intermediate Coronary Syndrome	Intracranial Embolism
Intracranial Thrombosis	Iron Deficiency Anemia
Labyrinthitis	Malignant Essential Hypertension
Mitral Valve Disease	Osteoporosis
Parkinson Disease, Late-Onset	Peripheral Vascular Disease
Protein-Energy Malnutrition	Schizophreniform Disorder
Sinoatrial Node Disease	Swallowing Disorders
Transient Cerebral Ischemia	Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:

Sources

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:

tremor; back pain; angina pectoris; chest pain; headache; syncope; edema; pain; chronic pain; sciatica; seizures; vertigo/dizziness; equilibration disorder; sleeplessness; transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Cerebrovascular Disease:

⁴⁵ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.45	ACE ACHE AGTR1 APOB APOE APP
2	growth/size/body region	MP:0005378	10.39	ACE ACHE AGTR1 APOB APOE APP
3	nervous system	MP:0003631	10.38	ACHE AGTR1 APOB APOE APP CBS
4	cardiovascular system	MP:0005385	10.35	ACE ACHE ACTA2 AGTR1 APOB APOE
5	muscle	MP:0005369	10.33	ACHE ACTA2 APOB APOE APP CBS
6	cellular	MP:0005384	10.31	ACE APOB APOE APP CBS COL4A1
7	immune system	MP:0005387	10.28	ACE ACHE AGTR1 APOB APOE APP
8	behavior/neurological	MP:0005386	10.27	ACE ACHE AGTR1 APOE APP CBS
9	renal/urinary system	MP:0005367	10.16	ACE AGTR1 APOE CBS COL4A1 CX3CR1
10	reproductive system	MP:0005389	10.15	ACE ACHE APOB APOE APP CBS
11	liver/biliary system	MP:0005370	10.14	ACE APOB APOE CBS MEG3 MTHFR
12	respiratory system	MP:0005388	10.06	ACHE APOE CBS COL4A1 F2 MEG3
13	vision/eye	MP:0005391	10.03	ACHE ACTA2 APOB APOE APP CBS
14	skeleton	MP:0005390	10.02	APOE APP CBS CX3CR1 F2 HOTAIR
15	hematopoietic system	MP:0005397	9.97	ACE ACHE AGTR1 APOE APP CBS
16	mortality/aging	MP:0010768	9.86	ACE ACHE AGTR1 APOB APOE APP
17	integument	MP:0010771	9.32	APOE APP CBS CX3CR1 F2 MTHFR

Sources

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 759)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetylcarnitine

Approved, Investigational

Phase 4

3040-38-8

Nimodipine

Approved, Investigational

Phase 4

66085-59-4

4497

Nadroparin

Approved, Investigational

Phase 4

Progesterone

Approved, Vet_approved

Phase 4

57-83-0

5994

Spironolactone

Approved

Phase 4

1952-01-7, 52-01-7

5833

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Varenicline

Approved, Investigational

Phase 4

249296-44-4

5310966

Ezetimibe

Approved

Phase 4

163222-33-1

150311

Thrombin

Approved, Investigational

Phase 4

Lisinopril

Approved, Investigational

Phase 4

83915-83-7, 76547-98-3

5362119

Hydrochlorothiazide

Approved, Vet_approved

Phase 4

58-93-5

3639

Simvastatin

Approved

Phase 4

79902-63-9

54454

Atenolol

Approved

Phase 4

29122-68-7

2249

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Pantoprazole

Approved

Phase 4

102625-70-7, 138786-67-1

4679

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Dextromethorphan

Approved

Phase 4

125-71-3

5362449 5360696

Norepinephrine

Approved

Phase 4

51-41-2

439260

Doxazosin

Approved

Phase 4

74191-85-8

3157

Enalaprilat

Approved

Phase 4

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 4

75847-73-3

40466924 5388962 5362032

Galantamine

Approved

Phase 4

357-70-0, 1953-04-4

9651

Amiodarone

Approved, Investigational

Phase 4

1951-25-3

2157

Baclofen

Approved

Phase 4

1134-47-0

2284

Argatroban

Approved, Investigational

Phase 4

74863-84-6

152951 92722

Propafenone

Approved

Phase 4

34183-22-7, 54063-53-5

4932

Dronedarone

Approved

Phase 4

141626-36-0

208898

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Edaravone

Approved, Investigational

Phase 4

89-25-8

4021 70335

Allopurinol

Approved

Phase 4

315-30-0

2094 135401907

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Insulin glargine

Approved

Phase 4

160337-95-1

118984454

Pravastatin

Approved

Phase 4

81093-37-0

54687

Olmesartan

Approved, Investigational

Phase 4

144689-63-4, 144689-24-7

158781 130881

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 4

55-56-1

2713 9552079

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Tizanidine

Approved, Investigational

Phase 4

51322-75-9

5487

Trazodone

Approved, Investigational

Phase 4

19794-93-5

5533

Saxagliptin

Approved

Phase 4

361442-04-8

11243969

Quinidine

Approved, Investigational

Phase 4

56-54-2, 130-95-0, 804-63-7

1065 441074 3034034 8549

Triflusal

Approved, Investigational

Phase 4

322-79-2

9458

Telmisartan

Approved, Investigational

Phase 4

144701-48-4

65999

Isoflurane

Approved, Vet_approved

Phase 4

26675-46-7

3763

Esreboxetine

Approved, Experimental, Investigational

Phase 4

98769-81-4, 71620-89-8, 98819-76-2

65856

Carvedilol

Approved, Investigational

Phase 4

72956-09-3

2585

Lercanidipine

Approved, Investigational

Phase 4

100427-26-7

65866

Quinapril

Approved, Investigational

Phase 4

82586-55-8, 85441-61-8

54892

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Ramipril

Approved

Phase 4

87333-19-5

5362129

Interventional clinical trials:

(show top 50) (show all 6848)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease	Unknown status	NCT04346862	Phase 4	Acetyl-L-carnitine hydrochloride 500mg;Placebo
2	Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network)	Unknown status	NCT02684825	Phase 4
3	Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions	Unknown status	NCT02478346	Phase 4	Fluorescein Sodium
4	Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident	Unknown status	NCT02714478	Phase 4
5	Acute Cerebrovascular Events During Extracorporeal Circulation a Comparison of New Minimized Perfusion Circuit to Standard Cardiopulmonary Bypass	Unknown status	NCT00862160	Phase 4
6	Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)	Unknown status	NCT00108706	Phase 4	Candesartan
7	Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography	Unknown status	NCT02826200	Phase 4	Acenocoumarol
8	A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent	Unknown status	NCT02446730	Phase 4	Prasugel;Clopidogrel
9	The Potential Effect of Omega3 Supplement in Fish Oil on Infarced Areas in the Brain and Improvement of Neurological Functions fo Ischemic Stroke Patients	Unknown status	NCT04386525	Phase 4
10	Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke	Unknown status	NCT01862978	Phase 4	Heparin;Nadroparin;Placebo
11	Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke	Unknown status	NCT04275180	Phase 4	Argatroban
12	Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study	Unknown status	NCT02767999	Phase 4	Fluoxetine;Placebo
13	A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke.	Unknown status	NCT01863277	Phase 4	Melatonin;placebo
14	The Differentiation and Treatment Scheme of TCM Key Syndromes for the Treatment of Acute Disabling Ischemic Stroke: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial	Unknown status	NCT04199455	Phase 4	Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules);Placebo
15	Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.	Unknown status	NCT02728180	Phase 4	Xingnaojing injection
16	The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial	Unknown status	NCT00724724	Phase 4	Butylphthalide Soft Capsules;Aspirin
17	A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke	Unknown status	NCT04200781	Phase 4	Granules of Shengdi Dahuang Decoction;Placebo
18	An International Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Progesterone Combined Intranasal and Intramuscular Administration in Patients With Acute Hemorrhagic Stroke	Unknown status	NCT04143880	Phase 4	Progesterone
19	Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke	Unknown status	NCT02581371	Phase 4	Cerebrolysin infusion
20	Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke	Unknown status	NCT00747279	Phase 4	Intensive insulin therapy
21	Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke	Unknown status	NCT00874601	Phase 4	Diovan® (valsartan)
22	Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial	Unknown status	NCT03993236	Phase 4	Experimental: Rosuvastatin/Ezetimibe 10;Active Comparator: Rosuvastatin 20mg
23	Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study)	Unknown status	NCT02458755	Phase 4	High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
24	Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol	Unknown status	NCT02403349	Phase 4	Fimasartan;Valsartan;Atenolol
25	The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography	Unknown status	NCT00247533	Phase 4
26	Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm	Unknown status	NCT01097967	Phase 4
27	A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke	Unknown status	NCT01758536	Phase 4	Huatuo Zaizao Pills
28	A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke	Unknown status	NCT02152280	Phase 4	Danhong Injection;Normal Saline
29	Safety and Efficacy of the Tong-Fu-Xing-Shen Herbal Formula for Stroke-Associated Pneumonia (TFXSHF)	Unknown status	NCT04275219	Phase 4	Tongfu capsules;The Placebo of Tongfu capsules
30	Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy	Unknown status	NCT02122367	Phase 4
31	A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke	Unknown status	NCT02114736	Phase 4	Botulinum Toxin injection in the rectus femoris muscle
32	The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke.	Unknown status	NCT02618603	Phase 4	Botulinum toxin A;Triamcinolone Acetonide
33	The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation	Unknown status	NCT02646267	Phase 4	standard intensity warfarin;low intensity warfarin;dabigatran etexilate
34	Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke	Unknown status	NCT02643784	Phase 4	Rosuvastatin
35	Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke	Unknown status	NCT00552916	Phase 4
36	A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events	Unknown status	NCT01013532	Phase 4	Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
37	Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study	Unknown status	NCT02817503	Phase 4	Standard BP control;Moderate BP control;Intensive BP control
38	A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation	Unknown status	NCT02549963	Phase 4	Rivaroxaban
39	Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke	Unknown status	NCT00967408	Phase 4	Escitalopram;Placebo
40	Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults	Unknown status	NCT02505802	Phase 4	BoNT-A injection
41	Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity	Unknown status	NCT02358005	Phase 4
42	Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol	Unknown status	NCT02483169	Phase 4	cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
43	An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage	Unknown status	NCT00325793	Phase 4	Nicardipine
44	Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients	Unknown status	NCT02484027	Phase 4	Rosuvastatin
45	Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke	Unknown status	NCT01198496	Phase 4	Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
46	Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO	Unknown status	NCT01550588	Phase 4	Standard medical treatment
47	Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue	Unknown status	NCT01554787	Phase 4	Chinese Herb Astragalus membranaceus
48	Efficacy of Creative Therapy for Stroke Patients	Unknown status	NCT01455155	Phase 4
49	A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life	Unknown status	NCT01278498	Phase 4	Escitalopram;sugar pill
50	TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT	Unknown status	NCT03529149	Phase 4

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Pentoxifylline

Warfarin

Warfarin Sodium

WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: cerebrovascular disorders

Sources

Genetic Tests for Cerebrovascular Disease

Sources

Anatomical Context for Cerebrovascular Disease

Organs/tissues related to Cerebrovascular Disease:

MalaCards : Brain, Bone Marrow, Heart, Spinal Cord, Cortex, Endothelial, Bone

Sources

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 47726)

#	Title	Authors	PMID	Year
1	Acetazolamide improves cerebral hemodynamics in CADASIL. ⁵³ ⁶²	Huang L...Wang H	20227091	2010
2	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. ⁵³ ⁶²	Hackam DG...Canadian Hypertension Education Program	20485689	2010
3	The angiotensin II type 2 receptor in the brain. ⁵³ ⁶²	Horiuchi M...Iwai M	19861353	2010
4	Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). ⁵³ ⁶²	Gardener H...Rundek T	20028534	2009
5	APOE-related mortality: effect of dementia, cardiovascular disease and gender. ⁵³ ⁶²	Rosvall L...Fratiglioni L	18237822	2009
6	Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. ⁵³ ⁶²	Benn M	19200547	2009
7	Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice. ⁵³ ⁶²	Tang KF...Zhou JN	19633698	2009
8	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. ⁵³ ⁶²	Khan NA...Canadian Hypertension Education Program	19417859	2009
9	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. ⁵³ ⁶²	Feldman HH...Kavanagh S	18985627	2009
10	CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. ⁵³ ⁶²	Ungaro C...Quattrone A	19006080	2009
11	Report of two Chinese families and a review of Mainland Chinese CADASIL patients. ⁵³ ⁶²	Yin XZ...Zhao GH	19167727	2009
12	MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. ⁵³ ⁶²	Liem MK...van der Grond J	19139365	2009
13	Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. ⁵³ ⁶²	Perneczky R...Kurz A	19542606	2009
14	Age and apoE associations with complex pathologic features in Alzheimer's disease. ⁵³ ⁶²	Jicha GA...Knopman DS	18653200	2008
15	Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. ⁵³ ⁶²	Tasdemir N...Tasdemir MS	18576210	2008
16	New therapeutic targets in the neurovascular pathway in Alzheimer's disease. ⁵³ ⁶²	Zlokovic BV	18625452	2008
17	Cystatin C expression in ischemic white matter lesions. ⁵³ ⁶²	Umegae N...Yamaguchi S	18261165	2008
18	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. ⁵³ ⁶²	Khan NA...Canadian Hypertension Education Program	18548143	2008
19	Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. ⁵³ ⁶²	Galluzzi S...Frisoni GB	18511756	2008
20	New biochemical markers in acute coronary syndromes. ⁵³ ⁶²	Tousoulis D...Stefanadis C	18537608	2008
21	PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. ⁵³ ⁶²	Yaffe K...Health ABC Study	17052804	2008
22	Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. ⁵³ ⁶²	Volcik KA...Boerwinkle E	17420019	2007
23	Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. ⁵³ ⁶²	van Rijn MJ...van Duijn CM	17220293	2007
24	Polymorphisms in apolipoprotein B and risk of ischemic stroke. ⁵³ ⁶²	Benn M...Tybjaerg-Hansen A	17595251	2007
25	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. ⁵³ ⁶²	Khan NA...Canadian Hypertension Education Program	17534460	2007
26	Silent brain infarction and platelet activation in obstructive sleep apnea. ⁵³ ⁶²	Minoguchi K...Adachi M	17341649	2007
27	Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. ⁵³ ⁶²	Wanby P...Carlsson M	17212611	2007
28	A perspective on telmisartan and cardiovascular risk. ⁵³ ⁶²	Giles TD	17938615	2007
29	Delapril plus indapamide: a review of the combination in the treatment of hypertension. ⁵³ ⁶²	Cavalieri L...Cremonesi G	17506588	2007
30	Cognitive impact of subcortical vascular and Alzheimer's disease pathology. ⁵³ ⁶²	Chui HC...Vinters HV	17192928	2006
31	Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. ⁵³ ⁶²	Goto Y...Sugimoto H	17054909	2006
32	Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. ⁵³ ⁶²	Qiu C...Fratiglioni L	16945218	2006
33	Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. ⁵³ ⁶²	Bosco P...Gueant JL	16894458	2006
34	Cognitive frailty: Predementia syndrome and vascular risk factors. ⁵³ ⁶²	Panza F...Solfrizzi V	16023766	2006
35	Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. ⁵³ ⁶²	Ortego-Centeno N...Camello MG	16208431	2006
36	[The relationship between ApoE gene polymorphism and lipid parameters]. ⁵³ ⁶²	Xiao ZJ...Wu J	16335008	2005
37	The spectrum of mutations for CADASIL diagnosis. ⁵³ ⁶²	Federico A...Dotti MT	15995828	2005
38	Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. ⁵³ ⁶²	Wanby P...Carlsson M	16013194	2005
39	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephaloapthy (CADASIL): a hereditary cerebrovascular disease, which can be diagnosed by skin biopsy electron microscopy. ⁵³ ⁶²	Ishiko A...Tanaka M	15798438	2005
40	Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? ⁵³ ⁶²	Coller BS	15662026	2005
41	Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. ⁵³ ⁶²	Lavergne E...GENIC Investigators	15681302	2005
42	T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. ⁵³ ⁶²	Hattori H...Suzuki N	15644279	2005
43	[Mutations of genes associated with thromboses in ischemic stroke in patients with primary antiphospholipid syndrome]. ⁵³ ⁶²	Kalashnikova LA...Nasonov EL	16320685	2005
44	Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. ⁵³ ⁶²	Varda NM...Gregoric A	15858957	2005
45	The FABP2 gene polymorphism in cerebrovascular disease. ⁵³ ⁶²	Wanby P...Carlsson M	15527447	2004
46	ACE genotype and cognitive decline in an African-Caribbean population. ⁵³ ⁶²	Stewart R...Mann A	15465635	2004
47	Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. ⁵³ ⁶²	Hosomi N...Koziol JA	15361766	2004
48	123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. ⁵³ ⁶²	Lorberboym M...Lampl Y	15471834	2004
49	Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. ⁵³ ⁶²	Fatini C...Matucci-Cerinic M	15016346	2004
50	Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. ⁵³ ⁶²	Evans M...Rees A	15161326	2004

Sources

Genes for Cerebrovascular Disease

Genes related to Cerebrovascular Disease (0 elite genes):

(show top 50) (show all 94)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	154.65	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27613094
2	MEG3	Maternally Expressed 3	RNA Gene	153.13	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27651151
3	NOTCH3	Notch Receptor 3	Protein Coding	32.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	11861701 11578869 19139365 (more) 12480758 19006080 19167727 15798438 20227091 11310272 15995828
4	APOE	Apolipoprotein E	Protein Coding	24.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11388660 9306343 15084782 (more) 10867209 11160955 10522889 8488520 12417379 10362893 1440702 9436725 8615081 17984004 16335008 10877158 19633698 18301447 11421127 7841371 20305997 17192928 16945218 19542606 11384894 18576210 17052804 17580963 10436099 18653200 16023766 12480082 19466630 14512206 10519874 9222173 8303769 9701675 9409270 18237822 10910427 9052712
5	ACE	Angiotensin I Converting Enzyme	Protein Coding	23.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9273825 11155741 12925557 (more) 12474296 12454231 9242959 11861692 8610309 12006218 8713688 10681079 9785588 19417859 17938615 17506588 14508588 11859923 10939785 10669647 20485689 18548143 10575803 15016346 9489129 15858957 10934691 15465635 17534460
6	COL4A1	Collagen Type IV Alpha 1 Chain	Protein Coding	22.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
7	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	22.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11388660 10938012 16320685 (more) 10765003 11758232 9715796 14644077 16894458 15651339 9615905
8	ACTA2	Actin Alpha 2, Smooth Muscle	Protein Coding	21.54	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
9	SERPINA3	Serpin Family A Member 3	Protein Coding	20.88	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9040504 11289720 10978037 (more) 2147546
10	APOB	Apolipoprotein B	Protein Coding	20.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2347277 9229197 17595251 (more) 20028534 10529757 19200547 1440702 19551315 12212210
11	APP	Amyloid Beta Precursor Protein	Protein Coding	19.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16901640 17054909 15459432 (more) 8170579 18625452
12	SELP	Selectin P	Protein Coding	18.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11798806 17420019 15662026 (more) 17341649
13	CBS	Cystathionine Beta-Synthase	Protein Coding	18.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10938012 11758232
14	CX3CR1	C-X3-C Motif Chemokine Receptor 1	Protein Coding	17.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15644279 15681302
15	MTR	5-Methyltetrahydrofolate-Homocysteine Methyltransferase	Protein Coding	17.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11758232
16	ACHE	Acetylcholinesterase (Cartwright Blood Group)	Protein Coding	17.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18985627 10410569 12574580 (more) 12860497
17	AGTR1	Angiotensin II Receptor Type 1	Protein Coding	17.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17220293 19861353
18	PLAT	Plasminogen Activator, Tissue Type	Protein Coding	16.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	PON1	Paraoxonase 1	Protein Coding	16.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11388660 19233151 11409295
20	F2	Coagulation Factor II, Thrombin	Protein Coding	16.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	LPL	Lipoprotein Lipase	Protein Coding	16.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10821816 11680797 12636935 (more) 15896905 11127970
22	TSPO	Translocator Protein	Protein Coding	15.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10675213 9303025 9374335
23	SELPLG	Selectin P Ligand	Protein Coding	15.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11843835 17420019 12879153
24	F12	Coagulation Factor XII	Protein Coding	14.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10669178
25	MAPT	Microtubule Associated Protein Tau	Protein Coding	14.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	FABP2	Fatty Acid Binding Protein 2	Protein Coding	14.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15527447 16013194 17212611
27	AGT	Angiotensinogen	Protein Coding	14.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	MIR199A1	MicroRNA 199a-1	RNA Gene	14.24	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
29	F13A1	Coagulation Factor XIII A Chain	Protein Coding	14.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11841441
30	F5	Coagulation Factor V	Protein Coding	13.98	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	APOH	Apolipoprotein H	Protein Coding	13.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9512879 7661181 16208431 (more) 9458202 12840879 17041354 9921104
32	RECK	Reversion Inducing Cysteine Rich Protein With Kazal Motifs	Protein Coding	13.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11685040
33	ADA2	Adenosine Deaminase 2	Protein Coding	12.99	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
34	HTRA1	HtrA Serine Peptidase 1	Protein Coding	12.57	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
35	TCN2	Transcobalamin 2	Protein Coding	12.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	MTRR	5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase	Protein Coding	12.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	APOA1	Apolipoprotein A1	Protein Coding	12.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9619070 20028534 1440702
38	MIR126	MicroRNA 126	RNA Gene	11.8	DISEASES inferred ¹⁴ ¹⁴
39	MIR124-1	MicroRNA 124-1	RNA Gene	11.31	DISEASES inferred ¹⁴ ¹⁴
40	MIR21	MicroRNA 21	RNA Gene	11.27	DISEASES inferred ¹⁴ ¹⁴
41	ARIH1	Ariadne RBR E3 Ubiquitin Protein Ligase 1	Protein Coding	10.83	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
42	MIR9-1	MicroRNA 9-1	RNA Gene	10.7	DISEASES inferred ¹⁴ ¹⁴
43	H2AC18	H2A Clustered Histone 18	Protein Coding	10.67	DISEASES inferred ¹⁴ ¹⁴
44	CST3	Cystatin C	Protein Coding	10.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18511756 18537608 18261165
45	HMGCR	3-Hydroxy-3-Methylglutaryl-CoA Reductase	Protein Coding	10.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17959252
46	MIR146A	MicroRNA 146a	RNA Gene	10.27	DISEASES inferred ¹⁴ ¹⁴
47	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	10.25	DISEASES inferred ¹⁴ ¹⁴
48	MIR223	MicroRNA 223	RNA Gene	10.23	DISEASES inferred ¹⁴ ¹⁴
49	MIR132	MicroRNA 132	RNA Gene	10.03	DISEASES inferred ¹⁴ ¹⁴
50	KRIT1	KRIT1 Ankyrin Repeat Containing	Protein Coding	10.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11854171

Sources

Variations for Cerebrovascular Disease

Sources

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Sources

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.43	PLAT NOTCH3 MTR F2 CX3CR1 COL4A1
2	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12.07	F2 APP APOE APOB
3	Binding and Uptake of Ligands by Scavenger Receptors ⁶⁶ Show member pathways Scavenging by Class A Receptors ⁶⁶ Scavenging by Class B Receptors ⁶⁶ Scavenging by Class F Receptors ⁶⁶ Scavenging by Class H Receptors ⁶⁶ Scavenging of heme from plasma ⁶⁶	11.56	COL4A1 APOE APOB
4	Methotrexate Pathway (Cancer Cell), Pharmacodynamics and Pharmacokinetics ⁶⁰ Show member pathways Antimetabolite Pathway - Folate Cycle, Pharmacodynamics ⁶⁰ One-carbon metabolism ⁷⁴ tetrahydrofolate salvage from 5,10-methenyltetrahydrofolate ⁶¹	11.32	MTR MTHFR CBS
5	amb2 Integrin signaling ⁶¹	10.9	SELP PLAT APOB
6	A-beta Plaque Formation and APP Metabolism ⁶⁵	10.69	PLAT APP ACE
7	Methionine metabolism ²²	10.63	MTR CBS
8	A-beta Uptake and Degradation ⁶⁵	10.43	CX3CR1 APP APOE ACE
9	Folate-alcohol and cancer pathway hypotheses ⁷⁴	10.09	MTR MTHFR CBS

Sources

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.36	SERPINA3 PON1 PLAT NOTCH3 F2 COL4A1
2	endoplasmic reticulum lumen	GO:0005788	10.07	F2 COL4A1 APP APOE APOB
3	blood microparticle	GO:0072562	9.86	APOE F2 PON1 SERPINA3
4	extracellular space	GO:0005615	9.7	SERPINA3 SELP PON1 PLAT F2 COL4A1
5	intermediate-density lipoprotein particle	GO:0034363	9.46	APOE APOB
6	high-density lipoprotein particle	GO:0034364	9.43	PON1 APOE APOB

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	cholesterol metabolic process	GO:0008203	9.86	PON1 APP APOE APOB
2	positive regulation of CoA-transferase activity	GO:1905920	9.8	APOE AGTR1
3	blood vessel diameter maintenance	GO:0097746	9.8	ACE AGTR1 CBS
4	homocysteine metabolic process	GO:0050667	9.78	MTHFR CBS
5	lipoprotein biosynthetic process	GO:0042158	9.76	APOE APOB
6	regulation of systemic arterial blood pressure by renin-angiotensin	GO:0003081	9.73	AGTR1 ACE
7	lipoprotein catabolic process	GO:0042159	9.71	APOE APOB
8	positive regulation of amyloid fibril formation	GO:1905908	9.67	APP APOE
9	artery morphogenesis	GO:0048844	9.63	NOTCH3 APOE APOB
10	low-density lipoprotein particle remodeling	GO:0034374	9.43	APOE APOB AGTR1
11	negative regulation of long-term synaptic potentiation	GO:1900272	9.1	CX3CR1 APP APOE

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	modified amino acid binding	GO:0072341	9.46	MTHFR CBS
2	heparin binding	GO:0008201	9.32	SELP F2 APP APOE APOB
3	bradykinin receptor binding	GO:0031711	9.26	AGTR1 ACE